Back to Market返回行情

CDXS Codexis, Inc.

USHealthcare
$2.43-5.08%ClosedMarket Cap: $220.9M

As of 2026-07-10 16:00

Why CDXS matters now

Codexis, Inc. (CDXS) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.43 with -5.08% on the session and $220.9M in market capitalization; recent performance reads 1-month +4.47% and YTD +57.67%.

The latest financial table shown here is Q1 2026, with revenue of $15.2M, net income of $-8.7M, and EPS of $-0.10. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -9.5%.

The latest indexable market news headline is "Codexis, Inc. (CDXS) Q1 2026 Earnings Call Transcript" from Seeking Alpha.

Additional event context on this page matters because analyst consensus is Buy with a median target of $5.00; recent insider activity includes De Vre Raymond filing A-Award. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

5.40

P/S

2.99

EV/EBITDA

-12.22

DCF Value

$-3.47

FCF Yield

-9.5%

Div Yield

0.0%

Margins & Returns

Gross Margin

83.9%

Operating Margin

-33.2%

Net Margin

-41.0%

ROE

-68.1%

ROA

-24.7%

ROIC

-22.0%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$15.2M$-8.7M$-0.10
Q4 2025$38.9M$9.6M$0.11
FY 2025$70.4M$-44.0M$-0.50
Q3 2025$8.6M$-19.6M$-0.22

Analyst Ratings

Consensus

Buy

Target (Consensus)

$5.00

Target (Median)

$5.00

Target Range

$5.00 - $5.00

Strong Buy: 1Buy: 4Hold: 2Sell: 0Strong Sell: 0

Trading Activity

Insider Trades

De Vre Raymonddirector
Sell2026-06-18
DILLY STEPHEN GEORGEdirector
Sell2026-06-18
Martinborough Estherdirector
Sell2026-06-18
Singhvi Rahuldirector
Sell2026-06-18
Smith David Vdirector
Sell2026-06-18

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

2.48

Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.